Letters
Hormone replacement therapy and venous thromboembolism
Postmenopausal hormone therapy and risk of venous thromboembolism: what about progesterone?
BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l601 (Published 11 February 2019) Cite this as: BMJ 2019;364:l601- Pierre-Yves Scarabin, emeritus research director
- Inserm U1018, Hôpital Paul Brousse, 94807 Villejuif, France
- pierre-yves.scarabin{at}inserm.fr
The UK study by Vinogradova and colleagues provides further evidence that oral but not transdermal oestrogen is associated with increased risk of venous thromboembolism among women who use postmenopausal hormone therapy.1 Previous studies have shown this safety advantage of transdermal oestrogen, together with the important role of concomitant progestogens.23
Progesterone is …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.